Potent 'new pressor protein' related to coagulation factor XII is potentiated by inhibition of angiotensin converting enzyme.
BACKGROUND
'New pressor protein' was observed after tryptic activation of human and rat plasma in vitro, which is done conventionally for prorenin measurements.


RESULTS
It is potently pressor, heat labile, possesses enzyme activity, and has a relative molecular mass > 30 kDa with isoelectric point(s) 4.7-4.9. New pressor protein equivalent to only 0.01 ml human, or rat, plasma injected intravenously quickly raises systolic blood pressure in 300 g anesthetized, ganglion-blocked, bioassay rats by about 15 mmHg. For unknown reasons, this is potentiated to about 45 mmHg after treatment with angiotensin I converting enzyme inhibitors (such as captopril and enalapril). New pressor protein activity in rats remains normal 24 h after bilateral nephrectomy, suggesting that it has an extrarenal origin and, furthermore, excluding the possibility of an association with renin-angiotensin system. Systolic blood pressure elevation is greater than the diastolic one, implicating cardiotonic effects. Human plasma new pressor protein was purified using standard biochemical techniques and its N-terminal sequence (19 residues) found to be homologous with the beta factor XIIa fragment of coagulation factor XII. This was supported by demonstrating inhibition of new pressor protein activity in vitro using the factor XII-specific corn trypsin inhibitor. Also, human new pressor protein activity in humans congenitally deficient in coagulation factor XII is very low. The high potency and multiphasic, cardiotonic effects of injected new pressor protein suggest that it interacts synergistically with other systems in the body. This was confirmed by showing that, within 10 min of total bilateral adrenalectomy, responses to new pressor protein decreased markedly.


CONCLUSIONS
New pressor protein's action requires adrenal (medullary?) involvement, but its mechanism of action and that of its potentiation by angiotensin converting enzyme inhibitors remain unknown. The physiologic and clinical relevance of these observations depends on whether activation of new pressor protein can occur in vivo.
Osmond
D H
DH
Department of Physiology, Faculty of Medicine, University of Toronto, Ontario, Canada. daniel.osmond@utoronto.ca
Mavrogiannis
L
L
Cotter
B R
BR
D000313:Adrenal Medulla / Q000502:physiology; D000315:Adrenalectomy; D000595:Amino Acid Sequence; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D001798:Blood Proteins / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D002216:Captopril / Q000494:pharmacology; D004792:Enzyme Precursors / Q000097:blood; D005174:Factor XII / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D005175:Factor XII Deficiency / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D007526:Isoelectric Point; D008297:Male; D008969:Molecular Sequence Data; D008970:Molecular Weight; D051381:Rats; D017208:Rats, Wistar; D012083:Renin / Q000097:blood; D012504:Saralasin / Q000494:pharmacology; D014361:Trypsin Inhibitors / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D001798:Blood Proteins; D004792:Enzyme Precursors; D014361:Trypsin Inhibitors; D005174:Factor XII; D002216:Captopril; D012083:Renin; D012504:Saralasin